RxDoctor Payments Data

Junyan Gu, MD

Vascular Surgery · Hagerstown, MDNPI 1144514340

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,509 of the $10,385 with a category attached, or 72.3%. 34 manufacturers reported payments, led by Medtronic at 37.9% of the total. Reporting peaked in 2022 at $3,230 and has fallen 59.1% since, to $1,322 in 2025.

$10,385in general payments, 2019–2025

Across 245 payments — averaging $42.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • W. L. Gore & Associates, Inc.$1K
  • Tactile Systems Technology Inc$903
  • Abbott$721
  • Boston Scientific$491
  • Cook Medical LLC$453
  • plus $3K from 28 others

What the payments were for

  • Travel & lodging$2,56125%
  • Food & beverage$7,50972%
  • Education$3153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,385 in reported general payments places this provider in the 75th percentile of 104 vascular surgery providers in Maryland.

See all vascular surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$672,964
Medicare patients
613
Services billed
1,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban98$73,905
EliquisApixaban11$5,781
Cilostazol327$5,578
Pentoxifylline145$4,125
ClopidogrelClopidogrel Bisulfate190$1,993
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen52$335
Doxycycline Hyclate12$81
Oxycodone Hcl23$69
Tramadol Hcl12$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$240$73,90598 claims
PfizerEliquis$271$5,78111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 104 vascular surgery providers in Maryland.

Other vascular surgery in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →